Sight Sciences, Inc.
3000 Sand Hill Road
Building 3, Suite 105
Menlo Park
California
94025
United States
Tel: 415-889-0550
Website: http://www.sightsciences.com/
Email: info@sightsciences.com
About Sight Sciences, Inc.
Sight Sciences, Inc. is a privately held ophthalmic medical device company whose mission is to revolutionize how we think about and treat the leading causes of eye disease. Founded in 2006, headquartered in Menlo Park, CA, and supported by leading medical technology and private equity investors, Sight Sciences is developing a range of highly innovative products that share a universal value proposition:• Meeting a Massive Unmet Clinical Need in Ophthalmology
• Addressing the Underlying Physiology of Disease
• Delivering Unparalleled Product Usability
• Offering a High Socioeconomic Impact
• Creating a Paradigm Shift in Treatment from Pharmaceuticals to Devices
YEAR FOUNDED:
2010
LEADERSHIP:
Founder and CEO: Paul Badawi
Founder and CTO: David Badawi
CMO: Robert Stamper
PRODUCTS:
VISCO360
TRAB360
115 articles about Sight Sciences, Inc.
-
Sight Sciences to Report First Quarter Financial Results on May 2, 2024
4/18/2024
Sight Sciences, Inc. announced it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 2, 2024.
-
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
4/2/2024
Sight Sciences, Inc. (Nasdaq: SGHT) announced today that data from studies of two of its proprietary glaucoma and dry eye technologies, the OMNI Surgical System (“OMNI”) and the TearCare System (“TearCare”), will be presented in two oral presentations and two posters at this year’s ASCRS Annual meeting April 5th to 8th in Boston, MA.
-
Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference
3/26/2024
Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will present at the upcoming 23rd Annual Needham Healthcare Conference being held virtually.
-
Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance
3/7/2024
Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company") today reported financial results for the fourth quarter and full year ended December 31, 2023, and initiated financial guidance for full year 2024.
-
Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024
2/22/2024
Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”) today announced it will report financial results for the fourth quarter and full year ended December 31, 2023, after the market close on Thursday, March 7, 2024.
-
Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting
2/14/2024
Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company") today announced the launch of the Ergo-Series of the OMNI® Surgical System in Europe, a technology that facilitates surgeons’ ability to perform minimally invasive, implant-free glaucoma procedures in adults with open-angle glaucoma.
-
Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules CapitalRefinancing replaces prior senior credit facility
1/23/2024
Sight Sciences, Inc., an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, announced the closing of an up to $65 million senior secured credit facility with Hercules Capital, Inc., a leader in customized debt financing for companies in life sciences and technology-related markets.
-
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
1/8/2024
Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today reported preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2023.
-
Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors
12/28/2023
Sight Sciences, Inc. announced by five Medicare Administrative Contractors to withdraw their final local coverage determinations for Micro-Invasive Glaucoma Surgery that were scheduled to take effect on January 29, 2024.
-
Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease
12/18/2023
Sight Sciences, Inc. announced the publication in Clinical Ophthalmology of the six-month primary results from the SAHARA randomized controlled trial.
-
Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology
12/8/2023
Sight Sciences, Inc. announced the acceptance for publication in Clinical Ophthalmology of the prospective, multi-center, three-year GEMINI 2 trial with long-term clinical outcomes for patients treated with the OMNI® Surgical System technology.
-
Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023
10/24/2023
Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced it will report financial results for the third quarter ended September 30, 2023, after the market close on Tuesday, November 7, 2023.
-
Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023
10/19/2023
Sight Sciences, Inc. announced they will be hosting a TearCare SAHARA Six Month RCT Results reception in San Francisco, CA on Friday, November 3, 2023 from 5:00 to 7:00 pm PT.
-
Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting
10/12/2023
Sight Sciences, Inc. announced the presentation of the full phase I results from the SAHARA randomized controlled trial.
-
Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS
10/3/2023
Sight Sciences, Inc. today announced the results of the large scale, comparative real-world clinical outcomes study of patients treated by three leading minimally invasive glaucoma surgery (“MIGS”) technologies.
-
Sight Sciences Provides Revenue Guidance for the Third Quarter of 2023 and Updates Revenue Guidance for Full Year 2023
9/11/2023
Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced third quarter 2023 revenue guidance and updated its revenue guidance for full year 2023.
-
Sight Sciences Appoints Matt Link as Chief Commercial Officer
9/11/2023
Sight Sciences, Inc., an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, announced the appointment of Matthew Link as its Chief Commercial Officer, effective September 11, 2023.
-
Sight Sciences to Present at the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference
8/30/2023
Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced plans to present at the upcoming Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY.
-
Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023
8/3/2023
Sight Sciences, Inc., an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, reported financial results for the second quarter ended June 30, 2023 and reaffirmed guidance for full year 2023.
-
Sight Sciences to Report Second Quarter 2023 Financial Results on August 3, 2023
7/20/2023
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced it will report financial results for the second quarter ended June 30, 2023, after the market close on Thursday, August 3, 2023.